2022
Willingness to Be Vaccinated Against COVID-19 Among People With HIV in the United States: Results From a National Survey
Wickersham JA, Meyer JP, Shenoi S, Altice FL, Barakat LA, Virata M, Olivares M, Maviglia F, Khati A, Shrestha R. Willingness to Be Vaccinated Against COVID-19 Among People With HIV in the United States: Results From a National Survey. Frontiers In Medicine 2022, 9: 886936. PMID: 35847816, PMCID: PMC9280331, DOI: 10.3389/fmed.2022.886936.Peer-Reviewed Original ResearchCOVID-19 infectionCOVID-19 vaccineCOVID-19Undetectable HIV viral loadCOVID-19 vaccination uptakeAnnual influenza vaccinationHIV viral loadVaccine-related concernsNational surveyHIV careInfluenza vaccinationVaccination uptakeViral loadVaccination programSevere diseasePWHVaccineHIVInfectionIntensive outreach effortsTotal populationUnited StatesParticipantsAnnual incomeVast majority
2018
Dolutegravir/rilpivirine for the treatment of HIV-1 infection
Dowers E, Zamora F, Barakat LA, Ogbuagu O. Dolutegravir/rilpivirine for the treatment of HIV-1 infection. HIV/AIDS - Research And Palliative Care 2018, 10: 215-224. PMID: 30464642, PMCID: PMC6220428, DOI: 10.2147/hiv.s157855.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHIV-1 infectionDolutegravir/rilpivirineAntiretroviral therapyImportant drug-drug interactionsClinical trial efficacyDrug-drug interactionsImproved safety profileLong-term toxicityDrug package insertsRegimen simplificationMaintenance therapyCombination regimensMedication adherenceSafety profileSafety dataTrial efficacyConference abstractsPackage insertsDrug AdministrationUS FoodPharmacokinetic propertiesGoogle ScholarInfectionLimited dataRilpivirine